8-K: ALX Oncology Holdings Inc. Annual Meeting Results

ALX Oncology Holdings Inc. reported voting results from its Annual Meeting held on June 10, 2026, with key proposals including director elections and executive compensation.

Summary

• ALX Oncology Holdings Inc. held its Annual Meeting of stockholders on June 10, 2026.
• The meeting included votes on the election of two Class II Directors, an advisory vote on executive compensation, and the ratification of the appointment of KPMG LLP as the independent registered public accounting firm.
• All director nominees, Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P., were elected.
• Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.
• The appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects routine corporate governance with strong shareholder support for key proposals, indicating stability.

Positives

• Director nominees Daniel Curran, M.D., Rekha Hemrajani, and Chris Takimoto, M.D., Ph.D., F.A.C.P. were elected with strong support.
• The advisory vote on executive compensation received majority approval from stockholders.
• The appointment of KPMG LLP as the independent auditor was ratified with overwhelming support.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the ratification of the auditor for the fiscal year ending December 31, 2026.

Industry Context

StockSavvy.ai notes that the strong shareholder support for director elections, executive compensation, and auditor ratification is typical for established companies and indicates general shareholder confidence in the current board and management's oversight.

Corporate Governance

Stakeholder Impact

• Shareholders: Confirmation of board composition and executive compensation policies, and continued auditor oversight.
• Management: Received advisory approval for compensation, reinforcing current strategies.
• Employees: Stability in leadership and governance provides a consistent operating environment.

Next Steps

• Directors elected will serve until the 2029 annual meeting of stockholders.
• KPMG LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Key Dates

Keywords

ALX Oncology Holdings Inc., Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, Independent Auditor, KPMG LLP, Corporate Governance